New interim YOLT-203 data in #PH1 to be presented today at #KidneyWeek2026, demonstrating durable reductions in urinary oxalate following a single administration. Read more:  yoltx.com/news/press-release… #ASNKidneyWk

YolTech will present interim clinical data from two ongoing YOLT-203 trials in primary hyperoxaluria type 1 (#PH1) at #KidneyWeek2026 in Denver. 📄 TH-PO0143 📅 Oct. 22 | 10 a.m. — 12 p.m. MT 📍Exhibit Hall A View abstract: asn-online.org/education/kid… #ASNKidneyWk

We appoints Nitin Patel, BM BCh, as U.S. CMO to bolster U.S. clinical leadership. Dr. Patel has 18+ years of experience covering clinical development, medical affairs and drug safety, rare disease and cell‑gene therapy, including senior roles at Legend Biotech, GSK and Freeline.

Join us at the #ERSCongress 2026: 📅 September 7, 2026, 12:30 – 14:00 CEST 📍 Fira Gran Via (Halls 1–3), Barcelona, Spain 📝 Late Breaking Abstract-Clinical Proof-of-Concept for In Vivo Base Editing in PI*ZZ Alpha-1 Antitrypsin Deficiency: Results from the YOLT-202 Early P1 Trial

YOLT-201 study in #ATTRCM to be presented at #ESC Congress 2026 📅 August 31, 09:40 CEST 📍 Science Box 4 (Research Gateway – Hall A1), Messe München 📌 In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial

Our first #PHOEN1X (#PH1-YOLT-203-200) study site is now active. For individuals and families affected by Primary Hyperoxaluria Type 1, please visit🔗 mytomorro.ws/ph1-socialAs Together, we remain committed to advancing #clinicalresearch for the #raredisease community.

Welcome Jessie Yeung to YolTech Therapeutics as Chief Financial Officer. Jessie brings deep biotech finance and capital markets expertise. We look forward to her partnership as we advance our pipeline and position YolTech for its next stage of growth.

At the 3rd Hope for Rare Science Conference (HRSC) in Shanghai. Yoltech shared latest progress in developing in vivo gene editing therapies for #raredisease and exchanged perspectives with researchers, clinicians and industry leaders from around the world.

Recapping the 2026 OHF International Hyperoxaluria Workshop in Prague. Dr. Matthew Breeggemann (UCSF), lead investigator of the YOLT-203 program, shared interim results from our IIT studies on YOLT-203. #Hyperoxaluria #RareDisease #GeneEditing